News & Events
- OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer
- OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits
- OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Designed to Arm the Immune System to Fight Cancer
We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.
Our core technology platform continues to advance through clinical trials for various cancers
Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer